blindness News
-
Blinds & Shutters Buyers’ Guide publishes December
The Blinds & Shutters Buyers' Guide, the only UK directory covering blinds, shutters, awnings and grilles, from finished product to components, machinery and services, was published in December 2011. This revised edition has 132 pages with information relating to 550+ businesses and 50 different product types, both internal and external shading products and services including Blinds; ...
-
Digital Diagnostics and Orbis International announce study to help save sight in Bangladesh
(Coralville, IA.) May 19, 2021 – Digital Diagnostics, developers of IDx-DR, an FDA De Novo-cleared autonomous AI system for the detection of diabetic retinopathy (DR) and diabetic macular edema (DME), and Orbis International, the influential nonprofit dedicated to fighting avoidable blindness around the world, have partnered on a study that will bring high-quality disease detection to ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases
LONDON – Friday 18 December 2020 – Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead ...
-
NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD). The trial will enroll up to 225 children with moderate ...
-
LayerBio CEO Presents Strategy to Develop a Sustained-Release Glaucoma Product at MIT VMS Demo Day 2014
Dr. Ken Mandell, Founder and CEO of LayerBio, spoke at MIT's Venture Mentoring Service - Demo Day 2014, an invitation-only event showcasing the latest start-up companies within the MIT community. In his presentation, Dr. Mandell discussed LayerBio's plans to develop a novel sustained-release therapy for treatment of glaucoma, the second leading cause of blindness ...
-
Artugen is currently enrolling in C. difficile infection study.
Artugen is currently enrolling subjects in “A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a C. difficileinfection” We are looking for volunteers to participate in a new study to help lower the recurrence rate of C. difficile infections. If you are someone who was diagnosed, treated, and recovered from the infection and are ...
-
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...
-
Blinds & Shutters - January 2021 (Issue One)
As the year begins, the vaccine is beginning to get rolled out and after the latest lockdown we will hopefully see some return to normality. It’s been a tough year for everybody in business and now that a Brexit deal has been achieved we hope there will be some clarity for exporters and importers from Europe. It has not all been doom and gloom for the blinds market as we have had ...
-
Digital Diagnostics Partners with Rapidly Scaling Medicare Advantage Organization, ArchWell Health
CORALVILLE, IOWA July 26, 2022 – Digital Diagnostics is proud to announce a partnership with ArchWell Health to bring IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (DR) – including diabetic macular edema (DME) – to ArchWell Health centers across the United States. “ArchWell Health is committed to improving patient outcomes and ...
-
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics ...
-
Guide to Sample Size Re-Estimation in Clinical Trials
About the webinar We explore common challenges faced when designing and conducting clinical trials with sample size re-estimation (SSR). Common SSR methods are explored along with their pros and cons. We have also examined some real-world examples of these methods, while taking a look at what advantages their use can bring. Further below, you will find the webinar recording, slides and worked ...
By Statsol
-
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow determination of the Maximum Tolerated Dose ...
-
Japanese Clinical Study of DiscGenics` Cell Therapy for Disc Degeneration Passes Initial Safety Review
Salt Lake City, UT and Tokyo, Japan – January 7, 2020 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has passed the initial planned safety review of its double-blinded clinical study evaluating ...
-
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. The amendment increases the study duration for patients to 48 ...
-
Blogpost - Scientific proof of the effectiveness of the REAplan
Robot-assisted therapy (RAT) is of significant interest in early rehabilitation, when neuroplasticity is high but motor control is frequently insufficient for patients to independently practice functional movements. Many patients with stroke experience persistent upper limb (UL) impairments. This single-blind, randomized, controlled trial[i] explored the impact of partially substituting ...
By Axinesis
-
NHS Long Term Plan gives thousands of life changing diabetes monitors
Nearly 30,000 people across the country with Type 1 diabetes have received life-changing diabetes monitors through the NHS Long Term Plan. The innovative device, which is the size of a £2 coin and worn on the arm, means people with Type 1 do not have to carry out multiple painful finger-prick checks to monitor their blood sugar levels. Instead, people with the condition can monitor their ...
-
BrainScope Surpasses Primary Endpoints in Multi-Year Department of Defense-Funded Validation Study for New Concussion Assessment Capability
BrainScope announced today that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion. In a large blinded validation study, the system demonstrated its ability to help clinicians assess concussion at the time of injury, reflect severity ...
-
Digital Diagnostics, Kingdom of Saudi Arabia Sign Intent to Provide Preventative Diabetic Healthcare to 35M
CORALVILLE, IOWA July 21, 2022 – Leadership from Digital Diagnostics – maker of IDx-DR, the first-ever FDA-cleared, fully autonomous AI system for the diagnosis of diabetic retinopathy – signed a memorandum of understanding (MOU) with the Kingdom of Saudi Arabia’s Ministry of Investment during a ceremonial visit with United States of America President Joe Biden. With this ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you